1. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle James, Hagop Kantarjian, Jan Burger, and Susan O’Brien
Blood
Volume 125(13):
March 26, 2015
©2015 by American Society of Hematology

2. Survival of patients after discontinuation of ibrutinib.
Survival of patients after discontinuation of ibrutinib. Patients survived for a median of 3.1 months after discontinuation of ibrutinib (n = 33).
Preetesh Jain et al. Blood 2015;125:
©2015 by American Society of Hematology

3. Postibrutinib survival of patients who progressed (without transformation; n = 7) vs those who transformed (n = 7).
Postibrutinib survival of patients who progressed (without transformation; n = 7) vs those who transformed (n = 7). Median survival in patients who progressed (untransformed) was not reached vs 2.6 months in those who transformed (P = .44).
Preetesh Jain et al. Blood 2015;125:
©2015 by American Society of Hematology